Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI), an international pharmaceutical company, today announced that Greg Deener has joined Sucampo Pharma Americas, Inc. (SPA), its wholly-owned subsidiary, as Vice President of Marketing, Strategy & Implementation.

He will be responsible for key marketing functions related to Sucampo’s approved drugs in addition to playing a key role in developing global marketing strategies for Sucampo’s pipeline compounds. He will report to Stanley G. Miele, Senior Vice President of Sales & Marketing of SPI and President of SPA.

“We are pleased to welcome Greg Deener to Sucampo and believe that he will assist us in maximizing the value of our approved drugs and our pipeline compounds. I believe that his contributions will help Sucampo get to the next level,” said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman and Chief Executive Officer of SPI.

Greg Deener has successfully led marketing and strategy functions at P&G, GSK and GTx, both in the U.S. and internationally, including GI experience on the Zantac^® and Metamucil^® brands. Greg Deener joins Sucampo from GTx, Inc., of Memphis, Tennessee, where he was Vice President, Marketing and Sales. Mr. Deener joined GTx in 2004 as Director, Marketing and Sales, and was promoted in January 2005 to Vice President. He led GTx’s commercial strategy, built its commercial organization and infrastructure, and oversaw development of the commercial positioning of all five of that company’s pipeline compounds. Prior to GTx, Mr. Deener worked at GlaxoSmithKline, from 1996 to 2003, where his responsibilities included leading the successful U.S. Avodart^® launch to both specialist and primary care physicians, professional and consumer promotional activities and lifecycle brand strategies; Therapy Marketing Director, Europe; Global Commercial Executive Director, CNS; Director, Global OTC Products. He also held a number of brand management and sales positions at The Procter and Gamble Company from 1983 to 1996. Mr. Deener graduated from the University of North Carolina-Chapel Hill with a B.S. in Business Administration.

Avodart and Zantac are registered trademarks of GlaxoSmithKline plc. Metamucil is a registered trademark of The Procter and Gamble Company.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company based in Bethesda, Maryland, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids was first identified by Dr. Ryuji Ueno, Sucampo’s Chairman and Chief Executive Officer. He founded Sucampo Pharmaceuticals in 1996 with Dr. Sachiko Kuno, founding Chief Executive Officer and currently Executive Advisor, International Business Development, and a member of the Board of Directors. For more information about Sucampo Pharmaceuticals, please visit www.sucampo.com.

source:http://www.businesswire.com